<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01127217</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ALOS-303</org_study_id>
    <nct_id>NCT01127217</nct_id>
  </id_info>
  <brief_title>Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Stage 2 Hypertension</brief_title>
  <official_title>The Multicenter, Randomized, Double Blind Phase 3 Clinical Trial to Compare Efficacy and Safety of Combination of Amlodipine and Losartan Compared to Amlodipine Monotherapy in Patients With Stage 2 Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the blood pressure lowering effects of an&#xD;
      amlodipine/losartan combination treatment and amlodipine monotherapy for treatment of Stage 2&#xD;
      hypertensive patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in MSSBP</measure>
    <time_frame>Baseline, Week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in MSSBP</measure>
    <time_frame>Baseline, Week 2 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline MSDBP</measure>
    <time_frame>Baseline, Week 2, 6, and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure responder rate</measure>
    <time_frame>Baseline, Week 2, 6, 8</time_frame>
    <description>Rate of patients who achieved target blood pressure (MSSBP &lt; 140 mmHg or MSDBP &lt; 90 mmHg), or MSSBP decrease &gt; 20 mmHg from baseline or MSDBP decrease &gt; 10 mmHg from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>amlodipine/losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine/losartan</intervention_name>
    <description>amlodipine 5mg/losartan 50mg, amlodipine 10mg/losartan 50mg (+HCTZ 12.5mg)</description>
    <arm_group_label>amlodipine/losartan</arm_group_label>
    <other_name>amosartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine</intervention_name>
    <description>amlodipine 5mg, amlodipine 10mg (+ HCTZ 12.5mg)</description>
    <arm_group_label>amlodipine</arm_group_label>
    <other_name>amodipin(amlodipine camsylate)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 aged or over&#xD;
&#xD;
          -  Patients with blood pressure measured at Visit 1; MSSBP≤180mmHg and MSDBP≤110 mmHg if&#xD;
             on anti-hypertensive drugs, 160mmHg≤MSSBP≤199mmHg and 80mmHg≤MSDBP≤119mmHg if not on&#xD;
             anti-hypertensive drugs&#xD;
&#xD;
          -  Patients with blood pressure measured at Visit 2 were 160mmHg≤MSSBP≤199mmHg and&#xD;
             80mmHg≤MSDBP≤119mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to stop all prior anti-hypertensive drugs safely during wash out period of 3&#xD;
             to 7 days&#xD;
&#xD;
          -  ≥ sitSBP 20mmHg or ≥ sitDBP 10mmHg of variation in three measurements from the&#xD;
             reference arm selected at Screening&#xD;
&#xD;
          -  History of hypersensitivity to dihydropyridines, angiotensin II receptor blockers or&#xD;
             thiazide diuretics&#xD;
&#xD;
          -  Secondary hypertension or suspected to be&#xD;
&#xD;
          -  Continuously took medicinal drugs that might affect blood pressure rather than&#xD;
             anti-hypertensive drugs more than 3 months&#xD;
&#xD;
          -  Type 2 diabetes mellitus which is not controlled or with type 1 diabetes mellitus&#xD;
&#xD;
          -  History of severe neurovascular disease, severe heart disease&#xD;
&#xD;
          -  Known as moderate or malignant retinopathy.&#xD;
&#xD;
          -  Renal diseases; serum creatinine ≥ 2mg/dl&#xD;
&#xD;
          -  Hepatic diseases; increase in ALT or AST ≥ 2xUNL&#xD;
&#xD;
          -  Anuria&#xD;
&#xD;
          -  Hyponatremia/hypokalemia or hypercalcemia&#xD;
&#xD;
          -  Active Gout&#xD;
&#xD;
          -  Surgical or medical diseases which might significantly change ADME of medicines&#xD;
&#xD;
          -  History of malignant tumor&#xD;
&#xD;
          -  Autoimmune diseases&#xD;
&#xD;
          -  History of alcohol or drug abuse&#xD;
&#xD;
          -  Positive to pregnancy test, nursing mother, woman with an intention of pregnancy&#xD;
&#xD;
          -  Considered inappropriate to participate in the clinical trial with any reason, based&#xD;
             on investigator's decision&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>8 Sites</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>May 19, 2010</study_first_submitted>
  <study_first_submitted_qc>May 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2010</study_first_posted>
  <last_update_submitted>September 12, 2010</last_update_submitted>
  <last_update_submitted_qc>September 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2010</last_update_posted>
  <keyword>amlodipine</keyword>
  <keyword>losartan</keyword>
  <keyword>hypertension</keyword>
  <keyword>stage 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

